What question did this study set out to answer?

To review primary mechanisms limiting CAR-T cell efficacy across solid and hematologic tumors and summarize novel engineering solutions designed to overcome these barriers.

April 6, 2021Blood Cancer JournalOpen Access

CAR-T cell therapy: current limitations and potential strategies

View Full Paper

Ask AI

Bookmark

Authors

RSRobert C. SternerUniversity of Wisconsin–Madison RSRosalie M. SternerMayo Clinic

Discussion

Member takes

Implication

Review outlines barriers and engineering solutions for CAR-T therapy across cancer types, highlighting strategies to reduce toxicity and enhance solid tumor infiltration.

Key Points

To review primary mechanisms limiting CAR-T cell efficacy across solid and hematologic tumors and summarize novel engineering solutions designed to overcome these barriers.
Narrative review synthesizing current literature on mechanistic challenges, adverse events, and engineering adaptations in CAR-T cell therapies.
Key clinical obstacles include life-threatening toxicities, modest persistence, antigen loss, and restricted trafficking across immunosuppressive tumor microenvironments.
Next-generation molecular engineering strategies focus on enhancing tumor infiltration, improving target specificity, and mitigating systemic toxicity.

Cite This Study

Sterner et al. (2021) studied this question.

synapsesocial.com/papers/69d71ae5ef370a38abf508b4 https://doi.org/10.1038/s41408-021-00459-7

View Full Paper

Ask AI

Bookmark

Implication

Review outlines barriers and engineering solutions for CAR-T therapy across cancer types, highlighting strategies to reduce toxicity and enhance solid tumor infiltration.

CAR-T cell therapy: current limitations and potential strategies

Discussion

Member takes

Implication

Key Points

Cite This Study

CAR-T cell therapy: current limitations and potential strategies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider